Renaissance Technologies LLC Purchases 309,500 Shares of ALX Oncology Holdings Inc. $ALXO

Renaissance Technologies LLC grew its position in shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) by 73.2% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 732,599 shares of the company’s stock after buying an additional 309,500 shares during the period. Renaissance Technologies LLC owned approximately 0.54% of ALX Oncology worth $1,469,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Bridgeway Capital Management LLC acquired a new position in shares of ALX Oncology in the third quarter valued at about $66,000. Invesco Ltd. acquired a new stake in ALX Oncology in the 1st quarter worth about $46,000. Seven Fleet Capital Management LP acquired a new stake in ALX Oncology in the 4th quarter worth about $133,000. AQR Capital Management LLC boosted its holdings in ALX Oncology by 183.6% in the 1st quarter. AQR Capital Management LLC now owns 119,050 shares of the company’s stock valued at $74,000 after purchasing an additional 77,065 shares during the period. Finally, State Street Corp boosted its holdings in ALX Oncology by 11.0% in the 4th quarter. State Street Corp now owns 124,228 shares of the company’s stock valued at $140,000 after purchasing an additional 12,300 shares during the period. Institutional investors and hedge funds own 97.97% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently commented on ALXO. Weiss Ratings cut shares of ALX Oncology from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, August 5th. Wall Street Zen upgraded ALX Oncology from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $4.60.

ALX Oncology Stock Up 4.1%

ALXO stock opened at $2.01 on Thursday. The company has a market cap of $277.94 million, a PE ratio of -1.78 and a beta of 0.42. The business has a 50-day simple moving average of $1.90 and a 200 day simple moving average of $1.95. ALX Oncology Holdings Inc. has a 52 week low of $0.62 and a 52 week high of $2.66. The company has a quick ratio of 9.71, a current ratio of 9.71 and a debt-to-equity ratio of 0.07.

ALX Oncology (NASDAQ:ALXO) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.01. Sell-side analysts anticipate that ALX Oncology Holdings Inc. will post -0.61 EPS for the current fiscal year.

ALX Oncology Profile

ALX Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Redwood City, California, focused on developing next-generation immuno-oncology therapies. The company’s mission is to harness and amplify both innate and adaptive immune responses to improve outcomes for patients with a range of solid tumors and hematologic malignancies.

The lead candidate in ALX Oncology’s pipeline is evorpacept (ALX148), a high-affinity CD47-blocking Fc-silenced fusion protein designed to enhance macrophage-mediated phagocytosis of cancer cells when combined with standard therapeutic antibodies or immune checkpoint inhibitors.